Thermo Fisher Scientific Inc. $TMO Stock Position Lifted by Simplicity Wealth LLC

Key Points

• Simplicity Wealth LLC increased its stake in Thermo Fisher Scientific by 56.5%, owning 2,273 shares worth $922,000 as of the latest SEC filing.
• Thermo Fisher's quarterly earnings surpassed expectations with $5.36 EPS reported, above the consensus estimate of $5.22, and revenues rose by 2.9% year-over-year to $10.86 billion.
• The firm recently declared a quarterly dividend of $0.43 per share, reflecting an annualized yield of 0.3%, scheduled for payment on October 15th.

Simplicity Wealth LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 56.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,273 shares of the medical research company's stock after acquiring an additional 821 shares during the quarter. Simplicity Wealth LLC's holdings in Thermo Fisher Scientific were worth $922,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. grew its holdings in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after purchasing an additional 45 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO opened at $544.44 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a market capitalization of $205.59 billion, a price-to-earnings ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The business has a 50 day moving average price of $483.77 and a two-hundred day moving average price of $446.95. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on TMO shares. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.